Zelluna Raises NOK 58.2M in Dual Offering to Fuel Clinical Advances
Event summary
- Zelluna ASA raised NOK 58.2M through a private placement (NOK 55M) and retail offering (NOK 3.2M)
- 3,143,958 new shares issued at NOK 18.50 per share
- Proceeds to support ZI-MA4-1 clinical development and strategic flexibility
- Initial clinical data from ZI-MA4-1 expected mid-2026
- Shares to commence trading on Euronext Oslo Børs on June 18, 2026
The big picture
Zelluna's successful fundraising positions it to advance its lead candidate, ZI-MA4-1, as the first MAGE-A4-targeting TCR-NK therapy. This financing comes as the biotech sector increasingly focuses on innovative cell therapies for solid tumors, where current treatments face significant limitations. The NOK 58.2M raise reflects investor confidence in Zelluna's platform, which combines NK cells' innate killing power with TCRs' precise tumor targeting. The company's ability to execute on its clinical timeline and translate scientific promise into commercial success will be critical in maintaining this momentum.
What we're watching
- Clinical Milestones
- How mid-2026 clinical data for ZI-MA4-1 will validate the MAGE-A4 targeting approach
- Financial Flexibility
- Whether the NOK 58.2M raise provides sufficient runway for additional strategic opportunities
- Market Positioning
- The pace at which Zelluna can establish leadership in off-the-shelf TCR-NK therapies for solid cancers
Related topics